Lab services company Charles River Laboratories (NYSE:CRL) reported Q2 CY2025 results beating Wall Street’s revenue ...

Charles River Laboratories' annual profit forecast raise on Wednesday was clouded by investor concerns about the higher number of order cancellations from clients, sending the contract research firm's ...

Charles River Laboratories on Wednesday raised its annual profit forecast, betting on growing demand for its drug discovery and development services from drugmakers, sending its shares up more than 4% ...

Overall, the initial steps of the wind-down will result the in the cancellation of nearly $500 million. Not all mRNA related ...

Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share of $3.12 – – Updates 2025 Guidance – WILM ...

Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and ...

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

Investing.com -- Charles River Laboratories International, Inc. (NYSE: CRL) shares jumped 6.9% after the company reported second-quarter earnings on Wednesday that significantly exceeded analyst ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions, including for Eli Lilly’s Kisunla.

Rocket Pharmaceuticals downgraded by BofA after FDA halts Danon disease trial; company pivots toward earlier-stage gene ...

Delhi High Court rules cyberbullying can be as traumatic as physical assault, upholding conviction in a case involving a minor victim and morphed ...